IP Library Granted Patent US 12,357,667
Granted Patent B2
US 12,357,667 · App. 17/815,878 · Granted Jul 15, 2025

Nutraceutical formulations to prevent, treat, and inhibit excess cytokines, SARS-CoV-2 spike proteins, and mRNA vaccine spike proteins

Inventor: Mark A Fluga (Negaunee, MI)
Assignee: Pono Lifestyle, LLC
A61K36/73A23L33/105A23L33/155A23L33/40A61K31/05A61K31/095A61K31/122A61K31/352A61K31/593A61K33/30A61K36/9066A61K38/06A61K38/4873
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,667
App. No.
17/815,878
Granted
Jul 15, 2025
Kind
B2
Abstract

Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and/or other virus spike proteins and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-CoV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.

Claims (54)

1. A nutraceutical composition comprising Cannabidiolic Acid, Cannabigerolic Acid, Cannabidiol, Cannabigerol, Vitamin D3, Vitamin K2, Magnesium, Quercetin, Zinc, Bromelain, Nigella Sativa /Thymoquinone, and Astaxanthin each present in therapeutically effective amounts, in an admixture with a nutraceutically acceptable excipient,

wherein the therapeutic effective amount for each of the named nutraceuticals is provided in a single or divided doses of twice daily or thrice daily, and wherein the therapeutic effective amount of Quercetin ranges from 125 mg to 500 mg, the therapeutic effective amount of Zinc ranges from 15 mg to 50 mg, the therapeutic effective amount of Vitamin D3 ranges from 100 mcg to 200 mcg, the therapeutic effective amount of Vitamin K2 ranges from 100 mcg to 200 mcg, the therapeutic effective amount of Magnesium ranges from 30 mg to 200 mg, the therapeutic effective amount of Bromelain ranges from 25 mg to 250 mg, the therapeutic effective amount of Cannabidiolic Acid ranges from 5 mg to 60 mg, the therapeutic effective amount of Cannabigerolic Acid 5 mg to 60 mg, the therapeutic effective amount of Cannabidiol ranges from 5 mg to 60 mg, the therapeutic effective amount of Cannabigerol ranges from 5 mg to 60 mg, the therapeutic effective amount of Nigella Sativa /Thymoquinone ranges from 100 mg to 1000 mg, and the therapeutic effective amount of Astaxanthin ranges from 4 mg to 12 mg.

2. The nutraceutical composition of claim 1 , wherein the therapeutic effective amount for each of the named nutraceuticals is provided in a single or divided doses of twice daily or thrice daily, and

wherein the therapeutic effective amount of Quercetin ranges from 140 mg to 450 mg,

the therapeutic effective amount of Zinc ranges from 20 mg to 45 mg,

the therapeutic effective amount of Vitamin D3 ranges from 90 mcg to 180 mcg,

the therapeutic effective amount of Vitamin K2 ranges from 90 mcg to 180 mcg,

the therapeutic effective amount of Magnesium ranges from 40 mg to 180 mg,

the therapeutic effective amount of Bromelain ranges from 30 mg to 225 mg,

the therapeutic effective amount of Cannabidiolic Acid ranges from 10 mg to 50 mg,

the therapeutic effective amount of Cannabigerolic Acid 10 mg to 50 mg,

the therapeutic effective amount of Cannabidiol ranges from 10 mg to 50 mg,

the therapeutic effective amount of Cannabigerol ranges from 10 mg to 50 mg,

the therapeutic effective amount of Nigella Sativa /Thymoquinone ranges from 150 mg to 900 mg, and

the therapeutic effective amount of Astaxanthin ranges from 6 mg to 10 mg.

3. The nutraceutical composition of claim 1 , wherein the therapeutic effective amount for each of the named nutraceuticals is provided in a single or divided doses of twice daily or thrice daily, and

wherein the therapeutic effective amount of Quercetin ranges from 175 mg to 500 mg,

the therapeutic effective amount of Zinc ranges from 30 mg to 50 mg,

the therapeutic effective amount of Vitamin D3 ranges from 120 mcg to 200 mcg,

the therapeutic effective amount of Vitamin K2 ranges from 120 mcg to 200 mcg,

the therapeutic effective amount of Magnesium ranges from 60 mg to 200 mg,

the therapeutic effective amount of Bromelain ranges from 50 mg to 250 mg,

the therapeutic effective amount of Cannabidiolic Acid ranges from 15 mg to 60 mg,

the therapeutic effective amount of Cannabigerolic Acid 15 mg to 60 mg,

the therapeutic effective amount of Cannabidiol ranges from 15 mg to 60 mg,

the therapeutic effective amount of Cannabigerol ranges from 15 mg to 60 mg,

the therapeutic effective amount of Nigella Sativa /Thymoquinone ranges from 200 mg to 1000 mg, and

the therapeutic effective amount of Astaxanthin ranges from 8 mg to 12 mg.

4. The nutraceutical composition of claim 1 , wherein the therapeutic effective amount for each of the named nutraceuticals is provided in a single or divided doses of twice daily or thrice daily, and

wherein the therapeutic effective amount of Quercetin ranges from 125 mg to 400 mg,

the therapeutic effective amount of Zinc ranges from 15 mg to 40 mg,

the therapeutic effective amount of Vitamin D3 ranges from 100 mcg to 150 mcg,

the therapeutic effective amount of Vitamin K2 ranges from 100 mcg to 150 mcg,

the therapeutic effective amount of Magnesium ranges from 30 mg to 150 mg,

the therapeutic effective amount of Bromelain ranges from 25 mg to 175 mg,

the therapeutic effective amount of Cannabidiolic Acid ranges from 5 mg to 40 mg,

the therapeutic effective amount of Cannabigerolic Acid 5 mg to 40 mg,

the therapeutic effective amount of Cannabidiol ranges from 5 mg to 40 mg,

the therapeutic effective amount of Cannabigerol ranges from 5 mg to 40 mg,

the therapeutic effective amount of Nigella Sativa /Thymoquinone ranges from 100 mg to 800 mg, and

the therapeutic effective amount of Astaxanthin ranges from 4 mg to 8 mg.

5. The nutraceutical composition of claim 1 , wherein the therapeutic effective amount for each of the named nutraceuticals is provided in a single or divided doses of twice daily or thrice daily, and

wherein the therapeutic effective amount of Quercetin ranges from 250 mg to 350 mg,

the therapeutic effective amount of Zinc ranges from 30 mg to 40 mg,

the therapeutic effective amount of Vitamin D3 ranges from 120 mcg to 160 mcg,

the therapeutic effective amount of Vitamin K2 ranges from 120 mcg to 160 mcg,

the therapeutic effective amount of Magnesium ranges from 30 mg to 200 mg,

the therapeutic effective amount of Bromelain ranges from 100 mg to 200 mg,

the therapeutic effective amount of Cannabidiolic Acid ranges from 15 mg to 40 mg,

the therapeutic effective amount of Cannabigerolic Acid 15 mg to 40 mg,

the therapeutic effective amount of Cannabidiol ranges from 15 mg to 40 mg,

the therapeutic effective amount of Cannabigerol ranges from 15 mg to 40 mg,

the therapeutic effective amount of Nigella Sativa /Thymoquinone ranges from 250 mg to 750 mg, and

the therapeutic effective amount of Astaxanthin ranges from 6 mg to 10 mg.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2024
From: FLUGA, MARK A, MR.
To: PONO LIFESTYLE, LLC
Reel/Frame 069206/0756 →
Continuity (2)
Provisional Application 63226197 · Jul 28, 2021
Related Publication 20230038577A1 · Feb 9, 2023
References Cited (31)
US 6566401B2 · Herzenberg et al. · 2003 [cited by applicant]
US 6576267B2 · Gelber et al. · 2003 [cited by applicant]
US 9241911B2 · Miller · 2016 [cited by applicant]
US 11026909B1 · Raju et al. · 2021 [cited by applicant]
US 11034655B1 · Vidhani et al. · 2021 [cited by applicant]
US 11116818B2 · Choe et al. · 2021 [cited by applicant]
US 11255855B1 · Huang et al. · 2022 [cited by applicant]
US 11266707B2 · Ichim et al. · 2022 [cited by applicant]
US 11324246B1 · Weis · 2022 [cited by applicant]
US 20110305765A1 · Mathur et al. · 2011 [cited by applicant]
US 20140141082A1 · Gao · 2014 [cited by applicant]
US 20160000854A1 · Osborne et al. · 2016 [cited by applicant]
US 20180140709A1 · Chancey · 2018 [cited by applicant]
US 20180271805A1 · Mezo · 2018 [cited by applicant]
US 20190169593A1 · Tarsio et al. · 2019 [cited by applicant]
US 20190192444A1 · Barzilay et al. · 2019 [cited by applicant]
US 20190313681A1 · Rosenstein · 2019 [cited by applicant]
US 20200060322A1 · Dimitrelos et al. · 2020 [cited by applicant]
US 20200138776A1 · Signorile · 2020 [cited by applicant]
US 20210220422A1 · Parker · 2021 [cited by applicant]
US 20210369674A1 · Wan · 2021 [cited by applicant]
US 20220016196A1 · Yimam et al. · 2022 [cited by applicant]
Stasilowicz, International Journal of Molecular Sciences, 22, 2021 (Year: 2021). [cited by examiner]
Amazon, Vaddmaan Astaxanthin++—60 Capsules, Amazon.in, May 16, 2019, accessed at https://www.amazon.in/Vaddmaan-Astaxanthin-Capsules-Curcumin-Antioxidant/dp/B07T71B5ZD?th=1, sheets 1, 4. [cited by applicant]
Goddek, S., ‘Vitamin D3 and K2 and their potential contribution to reducing the COVID-19 mortality rate’, International Journal of Infectious Diseases, Jul. 26, 2020, vol. 99, pp. 286-290. [cited by applicant]
Hernández, M. D. et al., ‘Evolution of COVID-19 patients treated with ImmunoFormulation, a combination of nutraceuticals to reduce symptomatology and improve prognosis: a multi-centred, retrospective cohort study’, medR… [cited by applicant]
Mrityunjaya, M. et al., “Immune-boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19”, Frontiers in Immunology, Oct. 7, 2020, vol. 11, Article No. 570122, pp. 1-12. [cited by applicant]
Nguyen, L. C. et al., ‘Cannabidiol Inhibits SARS-COoV-2 Replication and Promotes the Host Innate Immune Response’, bioRxiv, Mar. 10, 2021, pp. 1-15. [cited by applicant]
Pal, A. et al., ‘Zinc and COVID-19: basis of current clinical trials’, Biological Trace Element Research, Epub. Oct. 22, 2020, vol. 199, pp. 2882-2892. [cited by applicant]
Product catalog, #820 EPIC (Metabolic NO/ONOO Micro Antioxidant), Systemic Formulas, Oct. 2016, sheet 1. [cited by applicant]
International Search Report, issued on Dec. 30, 2022, in corresponding PCT Application PCT/US2022/074271 by Korean Intellectual Property Office, Korea. [cited by applicant]